Altimmune ALT Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's unrealized gains (losses) on available-for-sale securities?
- Altimmune (ALT) reported unrealized gains (losses) on available-for-sale securities of -$296K in Q1 2026.
- How has Altimmune's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Altimmune's unrealized gains (losses) on available-for-sale securities decreased by 886.7% year-over-year, from -$30K to -$296K.
- What is the long-term trend for Altimmune's unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2021 to 2025), Altimmune's unrealized gains (losses) on available-for-sale securities has grown at a 235.4% compound annual growth rate (CAGR), from $4K to $45K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric represents the change in the fair value of investment securities classified as available-for-sale that has not yet been realized through a sale. It captures fluctuations in the market value of these financial assets that are recorded directly in equity rather than through the income statement. Monitoring this figure helps investors understand the unrealized volatility and potential future liquidity impact of the company's investment portfolio.